Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males

NCT00814931 is registered in ClinicalTrials.gov with CeNeRx BioPharma Inc. as lead sponsor.

NCT NCT00814931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males
Lead sponsor
CeNeRx BioPharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2008
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, stress